Test of the month: The chromogenic antifactor Xa assay

Eric Gehrie, Michael Laposata

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

As the number of anticoagulant drugs increases and new ones are brought to market, the utility of the routine screening coagulation tests of today-namely the prothrombin time and activated partial thromboplastin time-will be significantly reduced in many clinical situations. Although the new anticoagulants are designed to require less frequent monitoring, it is imperative that the proper test is selected in situations where monitoring is needed. In addition, tests that are designed for the new generation of drugs may be informative in certain situations for monitoring the anticoagulants that have been in use for many years. Here, we present the chromogenic antifactor Xa assay and demonstrate its utility and its limitations in monitoring three anticoagulant drugs (unfractionated heparin, low molecular weight heparin, and fondaparinux) as well as one emerging anticoagulant, rivaroxaban.

Original languageEnglish (US)
Pages (from-to)194-196
Number of pages3
JournalAmerican Journal of Hematology
Volume87
Issue number2
DOIs
StatePublished - Feb 2012
Externally publishedYes

Fingerprint

Anticoagulants
Partial Thromboplastin Time
Low Molecular Weight Heparin
Prothrombin Time
Heparin
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Hematology

Cite this

Test of the month : The chromogenic antifactor Xa assay. / Gehrie, Eric; Laposata, Michael.

In: American Journal of Hematology, Vol. 87, No. 2, 02.2012, p. 194-196.

Research output: Contribution to journalArticle

@article{348add333ef6450eb7c02041ba61808d,
title = "Test of the month: The chromogenic antifactor Xa assay",
abstract = "As the number of anticoagulant drugs increases and new ones are brought to market, the utility of the routine screening coagulation tests of today-namely the prothrombin time and activated partial thromboplastin time-will be significantly reduced in many clinical situations. Although the new anticoagulants are designed to require less frequent monitoring, it is imperative that the proper test is selected in situations where monitoring is needed. In addition, tests that are designed for the new generation of drugs may be informative in certain situations for monitoring the anticoagulants that have been in use for many years. Here, we present the chromogenic antifactor Xa assay and demonstrate its utility and its limitations in monitoring three anticoagulant drugs (unfractionated heparin, low molecular weight heparin, and fondaparinux) as well as one emerging anticoagulant, rivaroxaban.",
author = "Eric Gehrie and Michael Laposata",
year = "2012",
month = "2",
doi = "10.1002/ajh.22222",
language = "English (US)",
volume = "87",
pages = "194--196",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Test of the month

T2 - The chromogenic antifactor Xa assay

AU - Gehrie, Eric

AU - Laposata, Michael

PY - 2012/2

Y1 - 2012/2

N2 - As the number of anticoagulant drugs increases and new ones are brought to market, the utility of the routine screening coagulation tests of today-namely the prothrombin time and activated partial thromboplastin time-will be significantly reduced in many clinical situations. Although the new anticoagulants are designed to require less frequent monitoring, it is imperative that the proper test is selected in situations where monitoring is needed. In addition, tests that are designed for the new generation of drugs may be informative in certain situations for monitoring the anticoagulants that have been in use for many years. Here, we present the chromogenic antifactor Xa assay and demonstrate its utility and its limitations in monitoring three anticoagulant drugs (unfractionated heparin, low molecular weight heparin, and fondaparinux) as well as one emerging anticoagulant, rivaroxaban.

AB - As the number of anticoagulant drugs increases and new ones are brought to market, the utility of the routine screening coagulation tests of today-namely the prothrombin time and activated partial thromboplastin time-will be significantly reduced in many clinical situations. Although the new anticoagulants are designed to require less frequent monitoring, it is imperative that the proper test is selected in situations where monitoring is needed. In addition, tests that are designed for the new generation of drugs may be informative in certain situations for monitoring the anticoagulants that have been in use for many years. Here, we present the chromogenic antifactor Xa assay and demonstrate its utility and its limitations in monitoring three anticoagulant drugs (unfractionated heparin, low molecular weight heparin, and fondaparinux) as well as one emerging anticoagulant, rivaroxaban.

UR - http://www.scopus.com/inward/record.url?scp=84855951618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855951618&partnerID=8YFLogxK

U2 - 10.1002/ajh.22222

DO - 10.1002/ajh.22222

M3 - Article

C2 - 22081480

AN - SCOPUS:84855951618

VL - 87

SP - 194

EP - 196

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 2

ER -